CD8A and COVID-19: A clinical trial demonstrated that Tα1 restored CD8+ and CD4+ T cell numbers in severe COVID-19 patients with lymphopenia and reversed the PD-1 and Tim-3 expression on exhausted/senescent CD8+ T cells.